RxDoctor Payments Data

Muntaz Majeed, MD

Internal Medicine · South Richmond Hill, NYNPI 1730258682

Payments from drug & device makers

$4,138in general payments, 2019–2025

Across 202 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$759
  • AstraZeneca$705
  • Amgen$536
  • Merck$247
  • Novo Nordisk$233
  • AbbVie$228
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,138 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,479
Medicare patients
91
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin104$120,031
JanuviaSitagliptin Phosphate89$89,119
JanumetSitagliptin Phos/Metformin Hcl55$57,916
Austedo XrDeutetrabenazine11$55,497
FarxigaDapagliflozin Propanediol47$54,109
LinzessLinaclotide84$53,230
EliquisApixaban42$46,194
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$18,952
XareltoRivaroxaban11$18,835
BrilintaTicagrelor25$18,536
EntrestoSacubitril/Valsartan17$18,148
TrulicityDulaglutide12$16,612
OzempicSemaglutide16$16,592
TradjentaLinagliptin11$15,630
Lactulose11$15,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$247$147,035144 claims
Boehringer IngelheimJardiance, Tradjenta$759$135,661115 claims
AstraZenecaFarxiga, Brilinta, Symbicort$705$76,79886 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$26$55,49711 claims
AbbVieLinzess$228$53,23084 claims
PfizerEliquis$24$46,19442 claims
Lilly USA, LLCTrulicity, Mounjaro$92$32,05927 claims
Johnson & JohnsonXarelto$224$18,83511 claims
NovartisEntresto$22$18,14817 claims
Novo NordiskOzempic$233$16,59216 claims
GSKBreo Ellipta$25$8,19422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in South Richmond Hill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →